SAN FRANCISCO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that it has entered into a third clinical trial collaboration and supply agreement with Merck (known as “MSD” outside the United States and Canada).
- Read more about Adagene collaborates with Merck for Third Clinical Trial for Keytruda
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/adagene-collaborates-with-merck-for-third-clinical-trial-for-keytruda
No comments:
Post a Comment